{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-028484","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.724597+00:00","generated_at":"2026-06-05T08:51:05.580817+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"uniQure reports $308.5M net loss in FY2023; cash $617.9M; pipeline programs advancing","bullets":["Net loss $308.5M ($6.47 per share) vs $126.8M ($2.71) in FY2022; revenue $15.8M vs $106.5M.","Cash and investments $617.9M as of Dec 31, 2023; expects to fund operations into Q2 2027.","Strategic reorganization expected to deliver $180M in cost savings over three years.","FDA clearance received for IND applications for AMT-260 (mTLE) and AMT-191 (Fabry); enrollment in Phase I/II trials expected H1 2024.","Regulatory interactions for AMT-130 (Huntington's) approval pathway expected in 2024; interim data update in mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-028484","json":"https://secwatch.observer/filing/0001104659-24-028484.json","markdown":"https://secwatch.observer/filing/0001104659-24-028484.md","text":"https://secwatch.observer/filing/0001104659-24-028484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465924028484/0001104659-24-028484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465924028484/tm246858d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:51:05.580817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85235955f28a1954bfb0e773727674257363ff3b","claim":"uniQure N.V. reported fourth quarter and full year 2023 results: revenue $15.8 million.","evidence_excerpt":"Company expects cash, cash equivalents and investment securities will fund operations into the second quarter of 2027. Revenues: Revenue for the year ended December 31, 2023 was $15.8 million, compared to $106.5 million in the same period in 2022. Revenues in 2022 included $100.0 million of license revenue related to the U.S. first sale milestone payment of HEMGENIX ®","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465924028484/0001104659-24-028484-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2023"},{"label":"Revenue","value":"$15.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}